COMPANY PROFILE / #3340
Deciphex
Dublin, IrelandVenture Capital-Backed
OVERVIEW
Developer of medical software applications designed for preclinical pathology. The company's applications use a combination of digital pathology and artificial intelligence to triage out high-volume, low complexity samples and specialize in human gastrointestinal and toxicological pathology use cases, enabling pathologists to focus on critical content and improve productivity.
已融资93.18
最新估值39.35
员工数220
成立年份2017
公司概况
- Companies
- Deciphex
- Description
- Developer of medical software applications designed for preclinical pathology. The company's applications use a combination of digital pathology and artificial intelligence to triage out high-volume, low complexity samples and specialize in human gastrointestinal and toxicological pathology use cases, enabling pathologists to focus on critical content and improve productivity.
- Website
- www.deciphex.com
- HQ Location
- Dublin, Ireland
- Year Founded
- 2017
- Keywords
- clinical pathology, digital pathology, digital pathology technology, drug development, medical software, medical software application
- Competitors
- Biotheranostics, PathologyWatch, Mendel, Deep Lens, microDimensions, Ibex Medical Analytics, SigTuple, Keen Eye, Qritive, Edda Technology, Judi, Definiens, PreciseDx, Hindsait, Proscia, Medic Vision Imaging Solutions, PathAI, Kheiron Medical Technologies, Inspirata, HealthEC, Niramai, Visiopharm, CureMetrix, PathXL, VoxelCloud, Clarify, Paige, Aiforia Technologies, PredxBio, Techcyte, Infervision, Comprehend, HealthMyne, KenSci, Dascena, Intelerad Medical Systems, Indica Labs, Novarad, Unlearn, Tempus AI, Aitia, C2i Genomics, Enlitic, iRepertoire, iCAD
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 93.18
- First Financing Date
- —
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 02-Oct-2025
- Last Financing Deal Type
- Debt - General
- Last Financing Size
- 15.00
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 39.35
- Last Known Valuation Date
- 16-Oct-2023
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 49.32
- Valuation Estimate Growth Rate
- 25.34%
- Active Investors
- Act Venture Capital, Charles River Laboratories International, Claret Capital Partners, Deciphex Nominees, Department of Enterprise, Trade and Employment, Enterprise Ireland, European Union, Furthr, GI Partners of Illinois, Halo Business Angel Network, Horizon 2020, Irrus Investments, Medtech Syndicate Nominee, Molten Ventures, NextSteps Capital, Novartis, Seroba Life Sciences, Stiftelsen Inova i Wermland, The Heart of the South West
- # Active Investors
- 19
- Acquirers
- —
团队与联系人
- Employees
- 220
- Employee Growth %
- 61.76%
- Employee History
- 2025: 220, 2024: 136, 2023: 119, 2022: 84, 2021: 60, 2020: 38 E, 2019: 16
- Primary Contact
- Donal O'Shea
- Primary Contact Title
- Co-Founder & Chief Executive Officer
- Primary Contact Email
- donal.oshea@deciphex.com
- Primary Contact Phone
- +353 (0)1 582 7193
增长与经营
- Revenue
- 6.20
- Revenue Growth %
- -13.04%
- Growth Rate
- 0.31%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 92
- Size Multiple
- 6.35x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 86
- Majestic Referring Domains
- 165
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 19%
- Success Probability Over Time – 3 Year
- 34%
- Success Probability Over Time – 5 Year
- 52%
记录来源：public.companies · 原始序号 #3340 · 所有字段均按数据库原值展示。